Carlo Patrono
#95,293
Most Influential Person Now
Researcher
Carlo Patrono's AcademicInfluence.com Rankings
Carlo Patronochemistry Degrees
Chemistry
#1536
World Rank
#2278
Historical Rank
Chemical Engineering
#103
World Rank
#116
Historical Rank
Organic Chemistry
#191
World Rank
#242
Historical Rank
Download Badge
Chemistry
Carlo Patrono's Degrees
- PhD Chemistry University of Milan
Why Is Carlo Patrono Influential?
(Suggest an Edit or Addition)Carlo Patrono's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). (2011) (5496)
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
- [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. (2016) (2910)
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. (2009) (1857)
- Platelet activation and atherothrombosis. (2007) (1843)
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (2013) (1418)
- Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. (2002) (1403)
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials (2006) (1399)
- Low-dose aspirin for the prevention of atherothrombosis. (2005) (1121)
- Platelet-active drugs: the relationships among dose, effectiveness, and side effects. (2004) (1008)
- Aspirin as an antiplatelet drug. (1994) (973)
- Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. (1982) (969)
- Efficacy and safety of low-dose aspirin in polycythemia vera. (2004) (856)
- The coxibs, selective inhibitors of cyclooxygenase-2. (2001) (823)
- Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (748)
- Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. (1980) (645)
- Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. (2005) (633)
- Thromboxane biosynthesis and platelet function in type II diabetes mellitus. (1990) (627)
- In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus (1999) (613)
- Platelet activation in obese women: role of inflammation and oxidant stress. (2002) (572)
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. (1983) (520)
- COVID-19 vaccines: where we stand and challenges ahead (2021) (510)
- In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. (1999) (500)
- Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. (1997) (475)
- The role of aspirin in cancer prevention (2012) (466)
- Clinical pharmacology of platelet cyclooxygenase inhibition. (1985) (428)
- Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
- Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (416)
- Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. (2005) (403)
- Platelet-active drugs : the relationships among dose, effectiveness, and side effects. (2004) (390)
- Lipid peroxidation in diabetes mellitus. (2005) (385)
- Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. (1995) (368)
- In Vivo Formation of 8-Epi-Prostaglandin F2α Is Increased in Hypercholesterolemia (1997) (347)
- Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. (1984) (336)
- 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. (2015) (327)
- Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets (2002) (320)
- The clinical significance of inhibition of renal prostaglandin synthesis. (1987) (318)
- Aspirin resistance: definition, mechanisms and clinical read‐outs (2003) (315)
- [2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. (2015) (300)
- Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. (2001) (272)
- Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". (2009) (250)
- Estimated rate of thromboxane secretion into the circulation of normal humans. (1986) (247)
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary (2014) (245)
- Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina (2000) (236)
- Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. (1997) (232)
- Evidence for a direct stimulatory effect of prostacyclin on renin release in man. (1982) (227)
- Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease (2002) (227)
- Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects (2004) (224)
- Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. (1999) (217)
- Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. (1985) (209)
- The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes (2012) (207)
- Antiplatelet drugs (2006) (193)
- Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia (1992) (189)
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. (2012) (187)
- Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia (1995) (184)
- Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
- Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. (2015) (181)
- Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. (2000) (181)
- Mechanisms, Consequences, and Prevention of Coronary Graft Failure (2017) (172)
- Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. (1997) (171)
- Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. (1983) (169)
- Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. (1997) (168)
- Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. (1993) (163)
- Leukotrienes in the rat central nervous system. (1984) (158)
- Platelet-Active Drugs (1998) (156)
- Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration (2003) (148)
- Aspirin and Cancer. (2016) (145)
- Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. (1987) (145)
- Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. (1999) (143)
- Oxidative Stress and Platelet Activation in Homozygous Homocystinuria (2001) (138)
- Dissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable Angina (1990) (136)
- Nutraceuticals in diabetes and metabolic syndrome. (2010) (135)
- Improvement of renal function with selective thromboxane antagonism in lupus nephritis. (1989) (133)
- Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials (2018) (132)
- Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. (1989) (129)
- Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. (1989) (129)
- Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis (2004) (128)
- Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. (2017) (127)
- Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. (1992) (126)
- THE SYNOVIAL PROSTAGLANDIN SYSTEM IN CHRONIC INFLAMMATORY ARTHRITIS: DIFFERENTIAL EFFECTS OF STEROIDAL AND NONSTEROIDAL ANTI‐INFLAMMATORY DRUGS (1981) (125)
- Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells (2016) (125)
- Failure of Thromboxane A2 Blockade to Prevent Attacks of Vasospastic Angina (1982) (124)
- Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. (1986) (121)
- Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease (1998) (120)
- Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease (2006) (119)
- Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. (2000) (118)
- In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. (1997) (117)
- Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. (2003) (113)
- Effects of Intravenous Prostacyclin in Variant Angina (1982) (112)
- Drug Insight: aspirin resistance—fact or fashion? (2007) (111)
- Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. (1994) (109)
- Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay (1982) (108)
- The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. (2015) (105)
- Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. (1989) (103)
- The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. (2010) (102)
- Platelet activation and lipid peroxidation in patients with acute ischemic stroke. (1997) (101)
- Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. (2006) (99)
- Increased Thromboxane Biosynthesis in Essential Thrombocythemia (1995) (97)
- Leukotriene C4 as a mediator of luteinizing hormone release from rat anterior pituitary cells. (1985) (96)
- Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? (1996) (96)
- Thromboxane synthesis and action within the kidney. (1992) (96)
- In vivo lipid peroxidation and platelet activation in cystic fibrosis. (2000) (95)
- Radioimmunoassay measurement of prostaglandins E2 and F2α in human urine (1979) (94)
- Determinants of Platelet Activation in Human Essential Hypertension (2004) (93)
- Aspirin: promise and resistance in the new millennium. (2008) (93)
- Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. (1993) (92)
- Increased Thromboxane Biosynthesis in Patients With Acute Cerebral Ischemia (1993) (92)
- Cardiovascular effects of cyclooxygenase‐2 inhibitors: a mechanistic and clinical perspective (2016) (91)
- Role of prostaglandin F2 in human cerebral vasospasm. (1974) (91)
- Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. (1999) (90)
- Determinants of the interindividual variability in response to antiplatelet drugs (2005) (90)
- Determinants of F2-isoprostane biosynthesis and inhibition in man. (2004) (87)
- Effects of the novel anti‐inflammatory compounds, N‐[2‐(cyclohexyloxy)‐4‐nitrophenyl] methanesulphonamide (NS‐398) and 5‐methanesulphonamido‐6‐(2, 4‐difluorothiophenyl)‐1‐indanone (L‐745, 337), on the cyclo‐oxygenase activity of human blood prostaglandin endoperoxide synthases (1995) (87)
- Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. (1995) (85)
- Insulin resistance as a determinant of platelet activation in obese women. (2006) (84)
- Induction of prostaglandin endoperoxide synthase‐2 in human monocytes associated with cyclo‐oxygenase‐dependent F2‐isoprostane formation (1996) (83)
- Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. (2018) (83)
- Nonsteroidal antiinflammatory drugs: past, present and future. (2009) (81)
- Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus (2010) (80)
- Evidence for a renal origin of urinary thromboxane B2 in health and disease. (1983) (80)
- Isoprostane formation and inhibition in atherothrombosis. (2005) (79)
- Reappraisal of the clinical pharmacology of low‐dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action (2014) (78)
- Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. (2013) (77)
- Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? (2013) (76)
- Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus (2003) (76)
- Characterization of furosemide-induced activation of the renal prostaglandin system. (1979) (76)
- Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. (1985) (74)
- Aspirin: new cardiovascular uses for an old drug. (2001) (74)
- Aspirin, 110 years later (2009) (74)
- Evidence for an extra-renal origin of urinary prostaglandin E2 in healthy men. (1979) (71)
- Role of aspirin in primary prevention of cardiovascular disease (2019) (71)
- Release of two vasodilators, adenosine and prostacyclin, from isolated rabbit hearts during controlled hypoxia. (1983) (70)
- Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide-stimulated cerebral blood flow in man. (1983) (69)
- Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. (2009) (67)
- Determinants of platelet activation in Alzheimer's disease (2007) (66)
- Mechanisms of Bleeding and Thrombosis in Myeloproliferative Disorders (1997) (62)
- Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. (2016) (62)
- Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. (1999) (62)
- Equal Antiplatelet Effects of Aspirin 50 or 324 mg/Day in Patients After Acute Myocardial Infarction (1985) (59)
- Off‐Pump Coronary Artery Bypass Grafting: 30 Years of Debate (2018) (56)
- A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. (2020) (55)
- Nonsteroidal Anti-Inflammatory Drugs and the Heart (2014) (55)
- Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. (1984) (54)
- Abstract 265: Insulin Resistance as a Determinant of Platelet Activation in Obese Women (2006) (53)
- Platelet activation and inhibition in unstable coronary syndromes. (1997) (53)
- Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings (1998) (52)
- Proarrhythmic Activity of Intracoronary Endothelin in Dogs: Relation to the Site of Administration and to Changes in Regional Flow (1991) (52)
- Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors (2011) (50)
- The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. (1995) (48)
- Physiologic variables affecting thromboxane B2 production in human whole blood. (1985) (48)
- Aspirin, platelet inhibition and cancer prevention (2018) (48)
- Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2016) (47)
- Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function. (1980) (47)
- Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. (1987) (47)
- Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. (1985) (44)
- Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention (1989) (44)
- Entry rate and metabolism of leukotriene C4 into vascular compartment in healthy subjects. (1992) (42)
- Thromboxane Biosynthesis in Cardiovascular Diseases (1990) (42)
- In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes (2015) (41)
- The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids (2001) (41)
- Cigarette smoking knowledge and perceptions among students in four Italian medical schools. (2012) (40)
- Measurement of Thromboxane Biosynthesis in Health and Disease (2019) (40)
- Radioimmunoassay in Basic and Clinical Pharmacology (1987) (40)
- In vivo platelet activation in diabetes mellitus. (1991) (39)
- Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. (1986) (38)
- The Relationships Among Dose, Effectiveness, and Side Effects (1998) (38)
- Rheumatoid knee synovitis successfully treated with intra-articular rifamycin SV. (1982) (37)
- Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. (1999) (36)
- Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs (2016) (35)
- Fractional conversion of thromboxane B2 to urinary 11-dehydro-thromboxane B2 in man (1988) (35)
- Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. (1989) (35)
- Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? (1998) (35)
- Helicobacter Pylori Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation (2004) (35)
- Effects of nabumetone on prostanoid biosynthesis in humans (1995) (35)
- Aspirin and Other COX-1 inhibitors. (2012) (33)
- Biosynthesis and pharmacological modulation of thromboxane in humans. (1990) (33)
- Increased thromboxane biosynthesis is associated with poststroke dementia. (1999) (33)
- Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. (1985) (33)
- Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. (1989) (32)
- Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post‐PRECISION: What We Thought We Knew Then and What We Think We Know Now (2017) (32)
- Effects of sulindac on renal and extrarenal eicosanoid synthesis (1987) (31)
- Inactivation of endothelin by polymorphonuclear leukocyte-derived lytic enzymes. (1991) (31)
- Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. (1995) (31)
- Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. (1990) (31)
- Type 2 Diabetes, Obesity, and Aspirin Responsiveness. (2017) (30)
- Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. (1992) (29)
- Low‐Dose Aspirin Acetylates Cyclooxygenase‐1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer (2017) (29)
- Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. (1993) (28)
- Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? (2002) (28)
- Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. (1993) (28)
- The PGH-Synthase System and Isozyme-selective Inhibition (2006) (27)
- The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis. (2021) (27)
- Pulmonary formation of prostacyclin in man. (1981) (27)
- Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. (1993) (26)
- The future of antiplatelet therapy in cardiovascular disease. (2010) (26)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (25)
- Antiplatelet agents in the prevention of diabetic vascular complications. (1993) (25)
- Effects of Unfractionated and Low Molecular Weight Heparins on Platelet Thromboxane Biosynthesis “In Vivo” (1994) (25)
- Comparative evaluation of the inhibitory effects of aspirin-like drugs on prostaglandin production by human platelets and synovial tissue. (1976) (25)
- Regulation of Endothelin‐1 Biosynthesis a (1994) (25)
- Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally? (2016) (24)
- PLATELET AND VASCULAR ARACHIDONIC ACID METABOLITES: CAN THEY HELP DETECT A TENDENCY TOWARDS THROMBOSIS? * (1984) (24)
- Aspirin for the prevention of coronary thrombosis: current facts and perspectives. (1986) (23)
- Comparison of low-dose aspirin and coronary vasodilators in acute unstable angina. (1990) (22)
- Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine. (1987) (22)
- On‐pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens (2017) (22)
- Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment (2010) (22)
- Release of Contracting Autacoids by Aortae of Normal and Atherosclerotic Rabbits (1992) (20)
- Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity. (2001) (20)
- Antiplatelet therapy: The P2Y12 receptor: no active metabolite, no party (2009) (19)
- Release of prostaglandin F1α and F2α from superfused platelets: Quantitative evaluation of the inhibitory effects of some aspirin-like drugs (1975) (19)
- Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. (1996) (19)
- Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. (1989) (19)
- Platelet activation in unstable angina (1989) (18)
- Inhibition of human platelet aggregation by stable analogs of prostacyclin. (1977) (18)
- In Silico Modeling of the Antiplatelet Pharmacodynamics of Low‐dose Aspirin in Health and Disease (2017) (18)
- Long Covid: where we stand and challenges ahead (2022) (18)
- Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism (2012) (18)
- Aspirin intolerance: unaltered susceptibility of platelet cyclo-oxygenase to inhibition by aspirin in vitro. (1978) (17)
- Echinococcus granulosus: evaluation of purified antigens immunoreactivity. (1974) (17)
- In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia (2014) (17)
- Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. (2006) (17)
- Effect of prostaglandin synthesis inhibitors on basal and CO2-stimulated cerebral blood flow in man. (1983) (16)
- [Expert consensus document on the use of antiplatelet agents]. (2004) (16)
- Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. (1992) (16)
- COVID 19: in the eye of the cytokine storm (2020) (16)
- Prostacyclin does not affect insulin secretion in humans. (1981) (15)
- Role of platelet and vascular eicosanoids in the pathophysiology of ischemic heart disease. (1987) (15)
- Measurement of thromboxane biosynthesis in man. (1989) (15)
- Leukotriene C4 stimulates LH secretion from rat pituitary cells in vitro. (1984) (14)
- Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. (1980) (14)
- CardioPulse: What's new in the 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2016) (14)
- Erratum: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (European Heart Journal (2013) 34 (3035-3087) Doi:10.1093/eurheartj/eht108) (2014) (14)
- Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. (2020) (14)
- A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. (1994) (13)
- Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium–Induced Colitis in Mice (2019) (13)
- Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial (2020) (13)
- The involvement of arachidonic acid metabolism in the control of renin release (1980) (13)
- Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement (2016) (13)
- In vivo expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site. (1993) (12)
- Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. (1981) (12)
- Thromboxane synthesis inhibitors and receptor antagonists. (1990) (12)
- Knowledge about Health Effects of Cigarette Smoking and Quitting among Italian University Students: The Importance of Teaching Nicotine Dependence and Treatment in the Medical Curriculum (2014) (12)
- Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cells. (1993) (12)
- Renal metabolism and urinary excretion of thromboxane B2 in the rat. (1989) (12)
- Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. (2004) (11)
- In vitro and in vivo inhibition of prostaglandin synthesis by fenoprofen, a non steroid anti-inflammatory drug. (1974) (11)
- In vivo thromboxane‐dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance (2020) (11)
- Platelet-dependent vascular occlusion (1994) (10)
- Evidence for a direct vasoconstrictor effect of big endothelin-1 in the rat kidney. (1992) (10)
- Biologic and methodologic variables affecting urinary prostaglandin measurement. (1980) (10)
- Rifamycin SV in the Treatment of Knee Synovitis. (1982) (10)
- Cardiac formation of prostacyclin during cardioplegia in man. (1982) (10)
- Selective COX-2 inhibitors: where do we go from here? (2008) (10)
- Platelet progenitors: the hidden drug target. (2015) (10)
- Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. (2020) (10)
- Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. (1991) (9)
- Dyslipoproteinemia in an inbred rat strain with spontaneous chronic progressive nephrotic syndrome. (1991) (9)
- Radioimmunoassay of prostaglandin F2alpha in unextracted human plasma. (1973) (9)
- Transforming the future of ageing (2019) (9)
- NOS Evaluations in Human Dental Pulp-Capping with MTA and Calcium-Hydroxide (2007) (9)
- Thromboxane biosynthesis and metabolism in cardiovascular and renal disease. (1993) (9)
- Thromboxane biosynthesis and pulmonary function in cystic fibrosis. (1995) (8)
- Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. (1983) (8)
- Efficacy and safety of aspirin in the long-term management of atherothrombosis. (2001) (8)
- Characterization of Biochemical and Functional Effects of Antiplatelet Drugs as a Key to Their Clinical Development (1995) (8)
- Heterologous in vivo processing of human preproendothelin 1 into bioactive peptides. (1991) (8)
- Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. (1995) (8)
- Prostaglandins and the kidney : biochemistry, physiology, pharmacology, and clinical applications (1983) (8)
- The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. (2021) (7)
- Antiplatelet strategies (2004) (7)
- Low-dose aspirin is a selective inhibitor of platelet cyclooxygenase activity in healthy subjects. (1983) (7)
- Induction of prostaglandin endoperoxide synthase 2 in monocytes of human whole blood is associated with cyclooxygenase-dependent isoprostane formation (1995) (7)
- Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia (2021) (7)
- Wytyczne ESC dotyczace postepowania w ostrych zespolach wiencowych bez przetrwalego uniesienia odcinka ST w 2015 roku. (2015) (7)
- Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. (2016) (6)
- Release of adenosine and prostacyclin from ischemic human hearts. (1983) (6)
- Prostaglandin E and F in Tooth Germs (1978) (6)
- Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. (2020) (6)
- Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial (2020) (6)
- Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety. (2013) (6)
- Variability in the Recovery Rate of Platelet Cyclooxygenase Activity During Chronic Therapy With Low-Dose Aspirin in Type 2 Diabetes. (2010) (6)
- Letter: Do pituitary prostaglandins play an essential role in the action of LH-RH in man? (1974) (6)
- Wytyczne ESC dotyczące postępowania w ostrych zespołach wieńcowych bez przetrwałego uniesienia odcinka ST w 2015 roku Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw postępowania w ostrych zespołach wieńcowych bez przetrwałego uniesienia odcinka ST (2015) (6)
- Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and i.v. glucose (1974) (6)
- [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD]. (2013) (6)
- Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. (1984) (6)
- Thromboxane biosynthesis and pharmacologic modulation in progressive glomerulosclerosis. (1989) (6)
- Pharmacologic modulation of arachidonic acid metabolism in man. A minireview with emphasis on radioimmunological methods used to quantitate drug effects. (1982) (6)
- CardioPulse: 'Ten Commandments' of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS). (2016) (5)
- Abstract 12233: Variability in the Recovery Rate of Platelet Cyclooxygenase Activity During Chronic Therapy With Low-Dose Aspirin in Type 2 Diabetes (2010) (5)
- Leukotriene C 4 as a mediator of luteinizing hormone release from rat anterior pituitary cells ( luteinizing hormone-releasing hormone / growth hormone / lipoxygenase products / hypothalamus ) (5)
- The role of prostaglandin synthesis inhibition in the renal syndromes associated with non-narcotic analgesics. (1986) (5)
- Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment. (1979) (5)
- Controversies in COX-2 inhibitor therapy: closing remarks. (2001) (5)
- Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. (1979) (5)
- Role of clinical pharmacology in the development of antiplatelet drugs. (2014) (5)
- Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. (1990) (5)
- The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. (2021) (5)
- Radioimmunoassay measurement of stable metabolites of platelet arachidonic acid: a convenient method for the in vitro and ex vivo evaluation of cyclo-oxygenase inhibitors. (1980) (5)
- Radioimmunoassay measurement of prostaglandins E2 and (1979) (5)
- Coxibs and traditional NSAIDs for pain relief – Authors' reply (2014) (5)
- Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines (2016) (4)
- Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial (2020) (4)
- Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors. (2014) (4)
- Early rhythm control for early atrial fibrillation? Comment on the EAST-AFNET 4 Trial. (2020) (4)
- Antiplatelet therapy: Aspirin for asymptomatic atherosclerosis? (2010) (4)
- Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. (1991) (4)
- Antiplatelet strategies*1 (2002) (4)
- The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. (2020) (4)
- The antiinflammatory compounds L-745,337 and NS-398 are selective inhibitors of prostaglandin endoperoxide synthase-2 in human blood monocytes (1995) (4)
- Non-steroidal anti-inflammatory drugs (2011) (4)
- Inhibition of renal prostaglandin synthesis in man: methodological and clinical implications. (1986) (4)
- Thromboxane biosynthesis in patients with systemic lupus erythematosus (1993) (4)
- Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors? (2020) (4)
- The role of thromboxane A2 in experimental and human models of chronic glomerular damage. (1989) (3)
- A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19 (2021) (3)
- Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. (2020) (3)
- PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. (2021) (3)
- Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial. (2020) (3)
- Human eicosanoid biosynthesis and metabolism. (1992) (3)
- Prostaglandins and other arachidonic acid metabolites in the pathogenesis of clinical and experimental glomerulonephritis. (1985) (3)
- Role of Platelet Activation in Dementia (1998) (3)
- Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians (2021) (3)
- Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context (2017) (3)
- Renal prostaglandins: biochemistry and functional significance in man. (1989) (3)
- Increased thromboxane biosynthesis in polycythemia vera (1991) (3)
- Aspirin at 120: Retiring, recombining, or repurposing? (2021) (3)
- Chapter 53 – Aspirin (2013) (3)
- Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI Trial. (2020) (3)
- Evidence for leukotriene formation and a neuroendocrine role for leukotriene C4 in rat brain. (1985) (3)
- Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. (1997) (3)
- The use of antiplatelet agents in glomerulonephritis: a pharmacological approach. (1990) (3)
- Clinical pharmacology of acetylsalicylic acid as an antiplatelet agent (1984) (3)
- Vitamin E inhibits enhanced F2 isoprostane biosynthesis in type IIA hypercholesterolemia (1996) (3)
- Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial. (2020) (2)
- Validation Criteria for Radioimmunoassay (1987) (2)
- Increased risk of incident diabetes in patients with long COVID. (2022) (2)
- Platelets in Thrombotic and Non-thrombotic Disorders: Aspirin (2002) (2)
- Physical activity and mortality reduction: is volume or intensity the key variable? (2021) (2)
- Fifty years with aspirin and platelets (2022) (2)
- Evaluation of urinary prostaglandin excretion by stop-flow analysis in dogs. (1981) (2)
- The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. (2020) (2)
- Release of prostaglandin F1alpha and F2alpha from superfused platelets: quantitative evaluation of the inhibitory effects of some aspirin-like drugs. (1975) (2)
- Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years (2022) (2)
- When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. (2021) (2)
- COX-2 expression and inhibition in human monocytes (1996) (2)
- Radioimmunoassay of 11-dehydrothromboxane B2. (1990) (2)
- The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. (2021) (2)
- Thromboxane-dependent platelet activation as a transducer of enhanced risk of coronary and cerebral thrombosis. (1991) (2)
- A SPRINT towards tighter control of blood pressure in hypertension. (2021) (2)
- The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’ (2020) (2)
- The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. (2021) (2)
- 1068 Direct Evidence for Long-Lasting Acetylation of Cyclooxygenase-1 Associated With Reduction of Colorectal Mucosa Prostaglandin E2 Levels and Ribosomal Protein S6 Phosphorylation by Low-Dose Aspirin in Subjects Undergoing Colorectal Cancer Screening (2016) (2)
- The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. (2021) (2)
- Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence (2011) (2)
- Drugs, prostaglandins, and renal function. (1985) (2)
- Acute, periprocedural and longterm antithrombotic therapy in older adults. (2022) (2)
- Abstract 17186: In Vivo Platelet Activation in Impaired Glucose Tolerance and During Progression of Type 2 Diabetes: a Cross-sectional and Longitudinal Study (2014) (2)
- Pharmacologic modulation of the cyclooxygenase pathway in the human kidney. (1990) (2)
- Preventing unintended pregnancy: let us count the ways (2006) (2)
- Cyclooxygenase enzymes in human vascular disease (1998) (2)
- Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism. (2021) (2)
- Response to “Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance” (2008) (2)
- Diabetes: Does aspirin increase the risk of major bleeds? (2012) (2)
- Neuropeptides and their Possible Role as Auxiliary Messengers (1986) (2)
- Aspirin continues to attract research and debate, 115 years after its synthesis. (2013) (2)
- Release of prostacyclin into the coronary venous blood in patients with coronary arterial disease. (1983) (2)
- An in silico model of aspirin-iduced inactivation of platelet and Megakaryocyte Cyclooxygenase-1 (2015) (1)
- Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation (2022) (1)
- Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction (2016) (1)
- 117. Hirudin does not affect the abnormally high thromboxane biosynthesis in homozygous homocystinuria (1996) (1)
- Measurement of arachidonate metabolites in urine by radioimmunoassay. (1985) (1)
- Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. (1985) (1)
- Iron heart. (2021) (1)
- Eicosanoid Biosynthesis and Metabolism in Myeloproliferative Disorders a (1994) (1)
- Occurrence of Leukotrienes in Rat Brain (1985) (1)
- StatinWISE sheds new light on statin-related muscle symptoms. (2021) (1)
- Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift? (2021) (1)
- A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine? (2021) (1)
- Time- and dose-dependence off inhibition off thromboxane biosynthesis by the selective thromboxane-synthase inhibitor FCE 22178 in diabetic patients (1990) (1)
- Solid evidence that very few muscle symptoms are due to statin therapy. (2022) (1)
- Oxidant stress in cardiovascular disease: an emerging modality or a disproved theory? (2001) (1)
- Alterations of renal arachidonate metabolism in chronic glomerular disease. (1986) (1)
- Indomethacin blunts the late phase of nitroglycerin-induced coronary vasodilatation in dogs. (1985) (1)
- Cardiovascular effects of low-dose aspirin, traditional non-steroidal anti-inflammatory drugs and coxibs. (2010) (1)
- Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes. (2022) (1)
- Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'. (2020) (1)
- Less Thromboxane, Longer Life. (2022) (1)
- Aspirin: 1A @ 125. (2022) (1)
- Efficacy of a Mediterranean diet for the secondary prevention of cardiovascular disease. (2022) (1)
- Studies of Isoprostane Biosynthesis in Man (1996) (1)
- Abstract 5786: Prostaglandin E2 and EP3 Activation Potentiate Human Platelet Responsiveness (2009) (1)
- Authors’ response to “Drug Insight: aspirin resistance—fact or fashion?” (2007) (1)
- PLATELETS AND VASCULAR OCCLUSION Clinical pharmacology of platelet cyclooxygenase inhibition (2005) (1)
- Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease. (2023) (1)
- Abstract 19137: Twice Daily Dosing Normalyzes the Impaired Antiplatelet Effect of Low-Dose Aspirin Due to Enhanced Platelet Turnover in Patients Undergoing On-Pump Cardiac Surgery (2016) (1)
- Preventing a diabetes pandemic through lifestyle intervention. (2021) (1)
- Prostanoid Generation in Platelet Function (2005) (1)
- Prostaglandin E2 and F2alpha in tooth germs. (1978) (1)
- Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention? (2021) (1)
- Prevention of myocarrdial infarction and stroke by aspirin-different merchanism? (1998) (1)
- Give genotype-guided dual antiplatelet therapy a second CHANCE. (2022) (1)
- Abstract 475: Overexpression of Platelet and Monocyte Cyclooxygenase-2 in Coronary Thrombi from Diabetic Patients: A Potential Mechanism of Aspirin Treatment Failure (2006) (1)
- PLATELET FUNCTION AND THROMBOXANE SYNTHESIS IN MYELOPROLIFERATIVE DISORDERS. RESPONSE (1993) (1)
- Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes? (2021) (1)
- 1447 – EVIDENCE FOR IN VIVO AND IN VITRO INHIBITION OF PROSTAGLANDIN (PG) SYNTHESIS IN HUMAN SYNOVIAI MEMBRANE BY ASPIRIN-LIKE DRUG (1977) (1)
- Guest authorship, mortality reporting, and integrity in rofecoxib studies. (2008) (1)
- Radioimmunoassay of prostaglandin F/sub 2a/ in unextracted human plasma (1973) (0)
- 389 ASPIRIN REDUCES PGE2 BIOSYNTHESIS TO LEVELS ASSOCIATED WITH REDUCED RISK OF ADENOMA AND COLORECTAL CANCER: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL. (2020) (0)
- Vitamin K antagonists remain the INVICTUS standard of care for patients with rheumatic heart disease and atrial fibrillation. (2022) (0)
- Impact of COX-2 deletion on platelet and megakaryocyte phenotypes (2013) (0)
- Prostanoids, aspirin and related compounds (2012) (0)
- A Double-Blind Randomized Study of the Antiplatelet Effects of Low-Dose ASA and Placebo in Patients After Myocardial Infarction (1983) (0)
- Long-term use of proton pump inhibitors and risk of diabetes mellitus: the totality of the evidence does not support a change in practice. (2022) (0)
- In vivo lipid peroxidation and platelet activation in Helicobacter pylori infection (2001) (0)
- Efficacy and safety of aspirin in the long-term management of atherothrombosis. (2002) (0)
- Book Review Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook Edited by Paolo Gresele, Valentin Fuster, José A. López, Clive P. Page, and Jos Vermylen. 511 pp., illustrated. New York, Cambridge University Press, 2008. $150. 978-0-521-88115-9 (2008) (0)
- Author and Subject Index (1998) (0)
- Effects of flurbiprofen and its nitroxybutylester derivative on the cycloxygenase activity of human blood prostaglandin endoperoxide synthases (1995) (0)
- Effect of prostanoids on the coronary circulation (1984) (0)
- EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. (2020) (0)
- [Innovation in COX-2 technology]. (2000) (0)
- Worsening of risk factor control in US diabetic patients: a call to action. (2021) (0)
- Th-P17:431 Analysis of free fatty acids in atherosclerotic plaques (2006) (0)
- Antiplatelet therapy to prevent graft failure after coronary artery bypass graft: aspirin monotherapy for most, DAPT for selected few. (2022) (0)
- Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects. (2022) (0)
- Aspirin for venous thromboprophylaxis after fracture: ready for prime time? (2023) (0)
- Low-dose aspirin in human disease states associated with enhanced thromboxane biosynthesis in vivo (1990) (0)
- Additive antithrombotic effect of a thromboxane-synthase inhibitor (TXSI) associated to a fully effective dose of a TXA2-receptor antagonist (TXRA): Comparison with aspirin (1992) (0)
- Aspirin: New aspects of a century-old drug (1992) (0)
- Vulnerable non-culprit coronary plaques: are they worth treating? (2021) (0)
- Lessons from ISIS-2 (1990) (0)
- Can targeting factor XIa dissociate thrombosis from haemostasis? (2022) (0)
- Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs. (2022) (0)
- The promise of selective aldosterone synthase inhibition for the management of resistant hypertension. (2022) (0)
- Differential effects of dazoxiben a selective thromboxane synthetase inhibitor on platelet and renal arachidonic acid metabolism in man (1983) (0)
- RENEB Inter-Laboratory Comparison 2021: The Cytokinesis-Block Micronucleus Assay. (2023) (0)
- [Radioimmunological assays: acceptable and questionable]. (1971) (0)
- Occluding to prevent occlusion. (2021) (0)
- Plasma and Synovial Levels of Tolmetin and Its Inhibitory Effect on Prostaglandins in Patients with Rheumatoid Arthritis (1982) (0)
- RENAL AND PLATELET EICOSANOIDS IN CHRONIC GLOMERULAR DISEASE (1989) (0)
- First in man: gene editing for the treatment of transthyretin amyloidosis. (2021) (0)
- Platelet reactivity in patients with stable cardiovascular disease using aspirin: correlation between different tests and association with subject characteristics (2011) (0)
- Anti-inflammatory drugs and renal synthesis of prostaglandins and thromboxane in patients with systemic lupus erythematosus (1987) (0)
- Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. (2020) (0)
- Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation? (2023) (0)
- The phenomenon of "resistance" to antiplatelet drugs (2006) (0)
- Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis? (2021) (0)
- Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges. (2022) (0)
- Thromboxane in lupus nephritis (1990) (0)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (0)
- A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally. (2021) (0)
- The ATLANTIC (Arterial Grafting International Consortium) Alliance (2017). Mechanisms, Consequences, and Prevention of Coronary Graft (2017) (0)
- Pro-arrhythmic effects of intracoronary endothelin in the dog (1990) (0)
- 332. Peripheral plasma concentrations of prostaglandin (PG) F1α and F2α in relation to estradiol (E2) and progesterone (P) during normal menstrual cycles (1974) (0)
- [Prostaglandins and ischemic cardiopathy]. (1980) (0)
- Abstract 5011: The Contribution of COX-1 and COX-2 to Platelet Activation in Essential Thrombocythemia: A Clinical Paradigm of Aspirin-resistant Thromboxane Biosynthesis (2009) (0)
- Contributors (2012) (0)
- Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. (2021) (0)
- DETERMINANTS OF PLATELET ACTIVATION IN HEART FAILURE (2007) (0)
- Abstract 3766: Determinants of Platelet Activation in Heart Failure (2006) (0)
- Entry rate and metabolic handling of LTC4 in the human circulation (1999) (0)
- A BRIGHT outlook for bivalirudin in patients with ST-segment elevation myocardial infarction. (2022) (0)
- 53 – Nonsteroidal antiinflammatory drugs (2015) (0)
- The PACMAN-AMI trial: game over for the "vulnerable plaque"? (2022) (0)
- The Effects of Low-Dose Aspirin and Selective Inhibitors of Thromboxane-Synthase on Eicosanoid Production in Man (1985) (0)
- Weekly Journal Scan The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis (2021) (0)
- Age-independent benefits of blood pressure lowering: are they applicable to all patients? (2022) (0)
- comments) vera: evidence for aspirin-suppressible platelet activation in vivo (see Increased thromboxane biosynthesis in patients with polycythemia (2011) (0)
- [Prevention of cardiovascular events with antiplatelet drugs: aspirin (and others)?]. (1999) (0)
- Antiplatelet agents in perspective (2003) (0)
- Book Review New Therapeutic Agents in Thrombosis and Thrombolysis Edited by Arthur A. Sasahara and Joseph Loscalzo. 681 pp., illustrated. New York, Marcel Dekker, 1997. $195. 0-8247-9866-X (1998) (0)
- A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. (2022) (0)
- Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19? (2022) (0)
- A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. (2021) (0)
- Meta-analysis of randomised trials drugs increase the risk of atherothrombosis? traditional non-steroidal anti-inflammatory Do selective cyclo-oxygenase-2 inhibitors and (2006) (0)
- CLINICAL TRIALS OF ANTITHROMBOTIC AGENTS IN UNSTABLE ANGINA (1987) (0)
- Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease (2022) (0)
- Another STEP towards tighter control of blood pressure in the elderly (2021) (0)
- Failure of testosterone and indomethacin to affect the LH response to synthetic LH-RH in normal men. (1975) (0)
- Contributors (2019) (0)
- Carlo Patrono and Felicita Andreotti Vascular Disease : Striking the Right Balance Between Efficacy and Safety Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic (0)
- Antiplatelet drugs for the prevention of coronary thrombosis (1988) (0)
- Assessment of Pharmacological Inhibition of PGH-Synthases in Man (1996) (0)
- Knowledge and perceptions of Medical Students about smoking behaviors: a survey in four Italian medical schools (2011) (0)
- [Antithrombotic treatment of acute coronary syndromes]. (2001) (0)
- The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. (2022) (0)
- 'Atom Heart Mothers': the risk of ischaemic heart disease in women with adverse pregnancy outcomes. (2023) (0)
- Gustav Born and life as “a series of ripples widening out from an original centre” (2018) (0)
- , Giovanni Ciabattoni , Enhanced Lipid Peroxidation Infection Causes Persistent Platelet Activation In Vivo Through (2004) (0)
- Thromboxane-dependent CD40L release in type 2 diabetes mellitus (2006) (0)
- In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure. (2022) (0)
- TheRelationship AmongDose, Effectiveness, andSideEffects (2017) (0)
- A SECURE polypill as a strategy at the heart of secondary prevention. (2022) (0)
- Leukotriene C4 as a mediator of lul rat anterior pituitary cells (luteinizing hormone-releasing hormone/growth hormone/lipoxygena (2016) (0)
- Nutritional Interventions Targeting the Pathogenesis of Diabetes Mellitus , Metabolic Syndrome , and their Complications Antioxidant Vitamins (2010) (0)
- Th-W51:4 Lipid peroxidation as a determinant of platelet activation in hypertensives with microalbuminuria (2006) (0)
- Out-of-Hospital Cardiac Arrest: Handle With Care-Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. (2020) (0)
- 47. Plasma levels of estriol, estradiol-17β, progesterone, 17-hydroxy-progesterone and prostaglandins-F1a and F2α pregnant women neat term (1975) (0)
- enrolled in a prospective observational study Acute leukemia in polycythemia vera: an analysis of 1638 patients (2013) (0)
- 2182 – DIRECT EVIDENCE FOR THE OVERALL ACTIVATION OF THE RENAL PROSTAGLANDIN SYSTEM BY FUROSEMIDE IN HUMANS (1978) (0)
- A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis. (1987) (0)
- Abstract 17744: In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes Mellitus (2014) (0)
- Tobacco related knowledge among students in medical schools before and after a lecture on nicotine dependence and treatment (2013) (0)
- Placing the risk of myopericarditis following COVID-19 vaccination into perspective. (2022) (0)
- Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding? (2021) (0)
- Bempedoic acid: a CLEAR therapeutic option for statin-intolerant patients? (2023) (0)
- Helicobacter pylori eradication as a gastroprotective strategy in elderly aspirin-treated subjects: established facts and unanswered questions. (2023) (0)
- Deletion of p66Shc gene restores endothelial function in a mouse model of obesity and insulin resistance. (2011) (0)
- INDEPENDENT DEVELOPMENT OF LOW-DOSE ASPIRIN AS AN ANTIPLATELET AGENT (2014) (0)
- The EHJ Weekly Journal Scan: Why? Who? How? (2020) (0)
- New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial. (2020) (0)
- Renal effects of thromboxane synthesis inhibitors and receptor antagonists (1990) (0)
- Differential cardiovascular effects of disease-modifying antirheumatic drugs in rheumatoid arthritis. (2022) (0)
- Coronary flowregulation inpatients withischemic heartdisease: release ofpurines andprostacyclin andtheelfect ofinhibitors ofprostaglandin formation (1985) (0)
- Tu-W26:7 Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinemia due to MTHFR C677T polymorphism (2006) (0)
- Leukotrienes in the rat central nervous system ( brain tissue / arachidonic acid metabolism / lipoxygenase pathway / leukotriene synthesis distribution / leukotriene C 4 immunoreactivity ) (0)
- ’ s response to reviews Title : Prognostic value of frailty in elderly patients with acute coronary syndrome : A systematic review and meta-analysis (2019) (0)
- P hromboxane-Dependent CD 40 igand Release in Type 2 Diabetes Mellitus (2016) (0)
- MECHANISMS OF ISOPROSTANE BIOSYNTHESIS IN HUMANS (1998) (0)
- thrombocythemia is explained by accelerated renewal of the drug target Aspirin-insensitive thromboxane biosynthesis in essential (2013) (0)
- Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy? (2021) (0)
- One-shot thrombolysis for the management of acute ischaemic stroke. (2022) (0)
- Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital (2021) (0)
- 118. Infusion of hirudin does not correct the abnormally high thromboxane A2 biosynthesis in homozygous homocystinuria (1996) (0)
- Precision Antiplatelet Therapy (2023) (0)
- Comprar Antiplatelet Agents | Paolo Gresele | 9783642294228 | Springer (2012) (0)
- Wytyczne ESC dotyczace cukrzycy, stanu przedcukrzycowego i chorob ukladu sercowo-naczyniowego opracowane we wspolpracy z EASD. (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Carlo Patrono?
Carlo Patrono is affiliated with the following schools:
